SEC Form 4 · accession 0001209191-17-028231
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Farah Champsi
Director
Period of report
Apr 24, 2017
Accepted (ET)
Apr 26, 2017 · 5:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 24, 2017 | S | 25,818 | $82.34 | D | 122,225 | I | See Footnote |
| Common StockF3,F2 | Apr 25, 2017 | S | 31,467 | $82.56 | D | 90,758 | I | See Footnote |
| Common StockF4,F2 | Apr 25, 2017 | S | 15,316 | $83.29 | D | 75,442 | I | See Footnote |
| Common StockF3,F2 | Apr 26, 2017 | S | 51,112 | $82.72 | D | 24,330 | I | See Footnote |
| Common StockF2 | Apr 26, 2017 | S | 200 | $83.06 | D | 24,130 | I | See Footnote |
| Common Stock | holding | — | — | — | 79,152 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.07 to $82.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F2The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.05 to $83.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.05 to $83.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.